These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21821528)

  • 21. State of the science of cardioprotection: Challenges and opportunities--proceedings of the 2010 NHLBI Workshop on Cardioprotection.
    Kloner RA; Schwartz Longacre L
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):223-32. PubMed ID: 21821520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological targets revealed by myocardial postconditioning.
    Burley DS; Baxter GF
    Curr Opin Pharmacol; 2009 Apr; 9(2):177-88. PubMed ID: 19109069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing infarct size in the setting of acute myocardial infarction.
    Downey JM; Cohen MV
    Prog Cardiovasc Dis; 2006; 48(5):363-71. PubMed ID: 16627050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: the role of Bcl-2 family proteins and ERK1/2.
    Lazou A; Iliodromitis EK; Cieslak D; Voskarides K; Mousikos S; Bofilis E; Kremastinos DT
    Apoptosis; 2006 Dec; 11(12):2195-204. PubMed ID: 17051325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning.
    Halkos ME; Kerendi F; Corvera JS; Wang NP; Kin H; Payne CS; Sun HY; Guyton RA; Vinten-Johansen J; Zhao ZQ
    Ann Thorac Surg; 2004 Sep; 78(3):961-9; discussion 969. PubMed ID: 15337028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardioprotection by volatile anesthetics.
    Bienengraeber MW; Weihrauch D; Kersten JR; Pagel PS; Warltier DC
    Vascul Pharmacol; 2005; 42(5-6):243-52. PubMed ID: 15922257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically useful cardioprotection: ischemic preconditioning then and now.
    Vander Heide R
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):251-4. PubMed ID: 21821524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies.
    Dirksen MT; Laarman GJ; Simoons ML; Duncker DJ
    Cardiovasc Res; 2007 Jun; 74(3):343-55. PubMed ID: 17306241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin: ready for prime-time cardioprotection.
    Riksen NP; Hausenloy DJ; Yellon DM
    Trends Pharmacol Sci; 2008 May; 29(5):258-67. PubMed ID: 18359096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desflurane-induced cardioprotection against ischemia-reperfusion injury depends on timing.
    Smul TM; Lange M; Redel A; Stumpner J; Lotz CA; Roewer N; Kehl F
    J Cardiothorac Vasc Anesth; 2009 Oct; 23(5):600-6. PubMed ID: 19167913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenylephrine induces early and late cardioprotection through mitochondrial permeability transition pore in the isolated rat heart.
    Naderi R; Imani A; Faghihi M; Moghimian M
    J Surg Res; 2010 Nov; 164(1):e37-42. PubMed ID: 20850771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning.
    Deuchar GA; Opie LH; Lecour S
    Life Sci; 2007 Apr; 80(18):1686-91. PubMed ID: 17316703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardioprotection of recombinant human erythropoietin pretreatment on ischemia-reperfused hearts and mechanism thereof: experiment with rats].
    Liu XM; Jia Z; Zhou ZQ; Xu JG
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2463-7. PubMed ID: 18067805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal morphine preconditioning induces cardioprotection via activation of delta, kappa, and mu opioid receptors in rats.
    Li R; Wong GT; Wong TM; Zhang Y; Xia Z; Irwin MG
    Anesth Analg; 2009 Jan; 108(1):23-9. PubMed ID: 19095826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preconditioning, postconditioning and their application to clinical cardiology.
    Kloner RA; Rezkalla SH
    Cardiovasc Res; 2006 May; 70(2):297-307. PubMed ID: 16516180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy.
    Miura T; Miki T
    Basic Res Cardiol; 2008 Nov; 103(6):501-13. PubMed ID: 18716709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition.
    Hönisch A; Theuring N; Ebner B; Wagner C; Strasser RH; Weinbrenner C
    Basic Res Cardiol; 2010 Mar; 105(2):155-67. PubMed ID: 19842009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of mitochondrial permeability transition pore opening: translation to patients.
    Gomez L; Li B; Mewton N; Sanchez I; Piot C; Elbaz M; Ovize M
    Cardiovasc Res; 2009 Jul; 83(2):226-33. PubMed ID: 19221132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ischemic postconditioning: an effective strategy of myocardial protection?].
    Rastaldo R; Penna C; Cappello S; Mancardi D; Pagliaro P; Losano G
    G Ital Cardiol (Rome); 2006 Jul; 7(7):464-73. PubMed ID: 16977786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metallothionein mediates cardioprotection induced by delayed preconditioning with adenosine A1 receptor agonist in rabbits].
    Xie C; Ran K; Liu J; Xu J; Chang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 34(7):603-7. PubMed ID: 19648671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.